Treatment discontinuation in pharmacological clinical trials for gambling disorder
Treatment discontinuation in pharmacological clinical trials for gambling disorder
Background: gambling disorder affects 0.5-2% of the population, and of those who receive treatment, dropout tends to be relatively high. Very little is known about participant-specific variables linked to treatment discontinuation/dropout in gambling disorder, especially in pharmacological clinical trial settings.
Methods: data were pooled from eight previous randomized, controlled pharmacological clinical trials conducted in people with gambling disorder who had never previously received any treatment for the disorder. Demographic and clinical variables were compared between those who did versus did not subsequently dropout from those treatment trials.
Results: the sample comprised data from 635 individuals, and the overall rate of treatment dropout was 40%. Subsequent treatment dropout was significantly associated with the following: positive family history of gambling disorder in one or more first degree relatives (relative risk [RR] of dropout in those with positive history vs not = 1.30), preference for mainly strategic vs non-strategic gambling activities (RR= 1.43), lower levels of education (Cohen’s D=0.22), and higher levels of functional disability (Cohen’s D=0.18). These variables did not differ significantly as a function of treatment condition (medication versus placebo). Dropouts and completers did not differ significantly in terms of the other demographic or clinical variables that were considered.
Conclusions: this study identified several candidate participant-specific predictors of pharmacological treatment dropout in gambling disorder. The findings highlight the need for future studies to address a wider range of contextual variables at large scale (including also study-specific variables e.g. trial/intervention duration), including in naturalistic treatment and clinical trial settings, with a view to developing algorithms that might usefully predict dropout risk.
pharmacotherapy, discontinuation, treatment, gambling
Chamberlain, Sam
8a0e09e6-f51f-4039-9287-88debe8d8b6f
Ioannidis, Konstantinos
0dfc1d89-41be-4d02-ae50-698117e80141
Grant, Jon E
07372bd5-8a0d-42b4-b41b-e376c652acf3
Chamberlain, Sam
8a0e09e6-f51f-4039-9287-88debe8d8b6f
Ioannidis, Konstantinos
0dfc1d89-41be-4d02-ae50-698117e80141
Grant, Jon E
07372bd5-8a0d-42b4-b41b-e376c652acf3
Chamberlain, Sam, Ioannidis, Konstantinos and Grant, Jon E
(2024)
Treatment discontinuation in pharmacological clinical trials for gambling disorder.
Journal of Psychiatric Research.
(In Press)
Abstract
Background: gambling disorder affects 0.5-2% of the population, and of those who receive treatment, dropout tends to be relatively high. Very little is known about participant-specific variables linked to treatment discontinuation/dropout in gambling disorder, especially in pharmacological clinical trial settings.
Methods: data were pooled from eight previous randomized, controlled pharmacological clinical trials conducted in people with gambling disorder who had never previously received any treatment for the disorder. Demographic and clinical variables were compared between those who did versus did not subsequently dropout from those treatment trials.
Results: the sample comprised data from 635 individuals, and the overall rate of treatment dropout was 40%. Subsequent treatment dropout was significantly associated with the following: positive family history of gambling disorder in one or more first degree relatives (relative risk [RR] of dropout in those with positive history vs not = 1.30), preference for mainly strategic vs non-strategic gambling activities (RR= 1.43), lower levels of education (Cohen’s D=0.22), and higher levels of functional disability (Cohen’s D=0.18). These variables did not differ significantly as a function of treatment condition (medication versus placebo). Dropouts and completers did not differ significantly in terms of the other demographic or clinical variables that were considered.
Conclusions: this study identified several candidate participant-specific predictors of pharmacological treatment dropout in gambling disorder. The findings highlight the need for future studies to address a wider range of contextual variables at large scale (including also study-specific variables e.g. trial/intervention duration), including in naturalistic treatment and clinical trial settings, with a view to developing algorithms that might usefully predict dropout risk.
Text
gambling_and_treatment_dropout_revised-clean
- Accepted Manuscript
Restricted to Repository staff only until 25 March 2025.
Request a copy
More information
Accepted/In Press date: 25 March 2024
Keywords:
pharmacotherapy, discontinuation, treatment, gambling
Identifiers
Local EPrints ID: 488517
URI: http://eprints.soton.ac.uk/id/eprint/488517
ISSN: 0022-3956
PURE UUID: f483d920-3655-4c78-a08e-6e712412e20e
Catalogue record
Date deposited: 26 Mar 2024 17:38
Last modified: 30 Aug 2024 02:00
Export record
Contributors
Author:
Sam Chamberlain
Author:
Konstantinos Ioannidis
Author:
Jon E Grant
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics